Next Phase Newsletter

A venture capital firm with multiple offices in China and Hong Kong, manages about USD 1 billion in committed capital with five USD funds and five RMB funds. The firm typically invests in series A and B rounds; however the firm prefers seed or angel rounds when it comes to overseas opportunities. The firm can invest anywhere from a few hundred thousand dollars up to ten million or more over a 10 year horizon. At present, the firm is looking for new investment opportunities in Greater China, while it also considers US- or EU-based companies with excellent technology that are Chinese-led or have a China angle.

The firm seeks to invest in a broad array of technologies including therapeutics, medical devices, IVD, e-Health and etc. Within therapeutics, the firm is interested in innovative drugs and novel biotechnology based therapies. Within medical devices, the firm is interested in a great range of devices and disposables that address large unmet medical need in China. The firm is opportunistic in terms of subsectors and stage of development. Historically, the firm invested in immuno-oncology drugs, CNS drugs, gene therapy and gene editing, digital health and AI-backed diagnostics, radiology imaging, clinical cell and molecular genetics testing, POC devices, diagnostics and genomics, and so on.

The firm is looking for competent and experienced management teams. The firm typically seeks a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare investment firm with offices in USA  actively finds and invests in life sciences companies (both public and private) that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. The firm makes investments ranging from $3 to $25 million depending on the target company’s stage of development and capital requirements. The firm considers investments into companies located anywhere around the globe.

The firm invests in breakthrough therapeutics, with a focus on oncology. However, the firm also considers investments into companies developing platform technologies. While the firm considers investment from seed stage to private investment in public equity, the firm’s ideal company has an asset that is pre-clinical or in early clinical trials.

The firm invests primarily in private companies but will also consider private investment in public equity opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm based in China was formed by professionals with R&D, entrepreneurial and investment experiences in both China and the US. The firm currently investing from its 300 million RMB (US$50 million) fund into early stage ventures in the life sciences and healthcare sector. Typical allocation size ranges from US$0.5-5 million. The firm can either lead or follow in a financing round. The firm is seeking opportunities from China and the US.

The firm works on a wide range of life science sectors including biopharmaceuticals, medical devices, diagnostics, life science R&D, and medical services. The firm is especially interested in clinical stage molecular diagnostic products, while it would also consider preclinical stage projects with a lesser interest. The firm is agnostic to disease indications.

The firm is looking for experienced management team with proven products. The firm can assist with registration and distribution in China by leveraging its network of pharma partners, CRO/CMO, academic centers, and distribution channels. The firm is interested in distribution rights in China and may request board representation on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm with offices throughout USA, Western Europe, and Asia invests specifically in companies that are raising funds to carry out clinical trials which can be performed, totally or in part, in an affiliated network of sites located in Europe and Asia. The firm typically invests alongside lead investors with a track record in biotech or medtech, and usually funds a large fraction of clinical trial costs. The firm can fund up to 10-15 trials per year. The size of investments is flexible, scaled to the clinical trial requirements, and will mostly range from 1 to 6 million USD/EUR. Investments made by the firm will fund work performed by a top-tier FDA-inspected network of sites offering clinical studies and CRO services to major pharma companies.

Although focused primarily on therapeutics, the firm will also consider diagnostics, medical devices, and digital health companies. The firm is generally indication-agnostic but has a keen interest in fields such as diabetes, pulmonology, ophthalmology and some cancers. The firm is primarily interested in companies running Phase I / Phase II clinical trials or equivalent.

The firm looks to act as a co-investor and will typically not require a board seat. The firm will more often invest when there is a lead investor on board. The firm has no specific requirements for the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading investment bank and investment fund headquartered in China is currently interested in investing in privately held companies in the Healthcare sector. The firm currently manages two funds, one of which only invests in China, and another early-stage fund that focuses on investments into US start-ups. The firm is planning to raise a second and much larger US fund in next 12 months. On average, the initial size of investment is in the $2-3M range.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, genomics, healthcare services and healthcare IT companies. With respect to medical devices, the firm is interested in devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled devices.

The firm prefers to act as the lead investor but is also open to co-investing. The firm will neither seek a board seat nor seek distribution rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global venture capital firm based in USA with additional offices throughout USA and Asia is investing from its newest fund (vintage 2017).  The firm invests broadly in the healthcare and technology sectors, in both venture and growth-stage financing rounds. Due to the firm’s large fund size, the firm generally only invests in rounds that raise $10 million or more. The firm makes investments globally.

Within healthcare, the firm focuses on biopharma, and also invests in medical devices, healthcare IT and healthcare service providers. The firm is generally not seeking opportunities in diagnostics.  In biopharma, The firm prefers to invest in companies that have obtained data from human clinical trials; however, the firm also invests in breakthrough therapeutic technologies at the preclinical stage.  In medical devices, the firm only invests in growth-stage companies with an approved product and initial revenues; the firm prefers to invest in breakthrough device technologies and avoids commodity markets.  The firm has a broad portfolio and is open to any indication area, but has a particular focus in oncology and orphan diseases, and typically does not invest in infectious diseases.

Within the service provision and IT sectors, the firm is focused on opportunities that provide cost savings to the healthcare system; in this sector, the firm’s expertise is primarily in companies that target healthcare providers as customers, but the firm is also open to considering other areas of the services/IT space.

The firm has no fixed requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture fund invests strategically on behalf of the parent company, which has a global presence. The firm is interested in life science opportunities globally, and expects to make 3-4 new investments per year. The firm typically invests about $10 million over the life of an investment.  The fund is typically a lead investor, and participates in syndicates with other investment firms. The firm does not attach rights or options to equity investments; the fund’s allocations are ‘no strings attached’. The firm considers opportunities globally but focuses on Europe, Middle East and North America.

The firm is strategically mandated to invest in opportunities with therapeutic platform technologies. The firm is only interested in novel technologies; while the fund will consider investing in any form of therapeutic technology, regenerative medicine, cell therapies and gene therapies are the areas of greatest interest. The fund is focused on investing in oncology (particularly immuno-oncology), but will also consider opportunities in other indication areas. The firm generally invests in preclinical assets.

The firm invests in technologies of strategic importance to the corporate. The firm only invests in privately held companies. The firm typically does not invest in single asset opportunities; only companies with multiple pipeline assets are of interest. The firm is often the first outside investor in a company, and prefers to invest in opportunities where the firm’s allocation can secure a meaningful stake in the company (a board seat is a requirement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.